Understanding the HI/HA Diagnosis
At a Glance
HI/HA syndrome is a rare GLUD1-related condition in which excess insulin causes low blood sugar, sometimes mistaken for epilepsy, while ammonia is usually only mildly elevated. Diagnosis relies on glucose testing during an episode and a critical blood sample.
For many parents, the journey to a Hyperinsulinism-Hyperammonemia (HI/HA) syndrome diagnosis is a confusing and frightening path [1]. You may have spent months or even years watching your child experience “episodes” or seizures that didn’t quite make sense, only to be told they had standard epilepsy [2]. This confusion often happens because the symptoms of low blood sugar can look exactly like a seizure, and unless a doctor checks the blood sugar at the exact moment of the event, the underlying metabolic cause remains hidden [3]. Learning that a diagnosis was missed can be frustrating, but finding the answer is the first step toward managing your child’s health with precision.
What is HI/HA?
In plain language, HI/HA syndrome is a rare genetic condition where the pancreas acts like a faulty thermostat [2]. It inappropriately releases insulin (the hormone that lowers blood sugar), even when the body doesn’t need it [4]. This causes blood sugar to drop to dangerously low levels (hypoglycemia). At the same time, the body produces high levels of ammonia in the blood, which is a metabolic byproduct usually detoxified by the liver into urea; in HI/HA, this process is altered [5].
While the ammonia levels are often high enough to provide a diagnostic clue, they are usually mild and do not typically cause the immediate symptoms that low blood sugar does [1][6]. The real danger and the likely cause of the “seizures” you may have witnessed is the brain being deprived of the sugar it needs to function [2].
What This Diagnosis Does—and Does Not—Mean
- Hypoglycemia: This means low blood sugar. It requires daily management and an emergency plan.
- Hyperammonemia: The high ammonia in HI/HA is usually mild. However, if your child ever experiences marked confusion, severe lethargy, or vomiting, seek medical care.
- Provoked Seizure vs. Epilepsy: A seizure provoked by low blood sugar is not the same as standard epilepsy, but do not stop any antiseizure medications without your neurologist’s approval.
Why Is It So Rare?
If your local pediatrician seemed unfamiliar with HI/HA, it is because the condition is exceptionally rare. Among children born with congenital hyperinsulinism (the broader group of disorders where the body makes too much insulin), only about 5% have the specific genetic pathogenic variant—known as a GLUD1 mutation—that causes HI/HA [7][1]. Because it is so uncommon, many healthcare providers may never see a single case in their entire career.
The Role of the GLUD1 Gene
Your child’s diagnosis is linked to a pathogenic variant in the GLUD1 gene [2]. This gene provides instructions for making an enzyme called glutamate dehydrogenase (GDH), which lives inside the mitochondria (the “powerhouses”) of cells [8].
In a healthy body, this enzyme is carefully controlled. It only speeds up when the body needs more energy. In HI/HA, the GLUD1 mutation makes this enzyme “overactive” [9].
- In the pancreas: The overactive enzyme signals the cells to release insulin even when blood sugar is already low [8].
- The Protein Trigger: This enzyme is especially sensitive to leucine, an amino acid found in protein [10]. This is why many children with HI/HA experience a sudden drop in blood sugar shortly after eating a high-protein meal, such as eggs or meat [7].
- In the liver: The same overactive enzyme leads to the overproduction of ammonia, which is why your child has the characteristic “hyperammonemia” part of the diagnosis [11].
The Diagnostic Journey and Misdiagnosis
The path to this diagnosis often starts with a “seizure-like” event in infancy or early childhood, with the median age of onset in some cohorts being around 8 months [5]. Because these events involve shaking or loss of consciousness, they are frequently mislabeled as epilepsy [2].
Standard epilepsy is a primary disorder of the brain’s electrical activity. In HI/HA, a seizure-like event may be provoked by low glucose, but glucose must be checked during the event [3]. Once doctors perform a critical sample (a blood test taken while the child’s blood sugar is low), they can see that the insulin action is inappropriately high and the ketones (an alternative fuel the body usually makes during fasting) are suppressed [4][12].
What the Research Says About the Future
Current medical research provides a clear path for treatment but also acknowledges some areas of uncertainty:
- Treatment Success: Research agrees that a medication called diazoxide is highly effective for almost all children with the GLUD1 variant [13][5]. Most children see their blood sugar stabilize quickly once the right dose is found [5].
- Neurodevelopmental Outcomes: While the blood sugar can be controlled, the long-term impact on a child’s development—such as learning, speech, and motor skills—can vary significantly [13]. Some children catch up and meet all their milestones, while others may face challenges like learning disabilities or speech delays [14][15]. This variability is why regular follow-ups with developmental specialists are an essential part of long-term care [13][16].
Finding the right diagnosis is often the hardest part of the journey. Now that you know the cause is metabolic, you and your medical team can focus on the specific tools needed to keep your child’s blood sugar stable and support their growth [3].
Common questions in this guide
What is HI/HA syndrome, and what causes it?
Why can HI/HA episodes look like epilepsy?
How is HI/HA syndrome diagnosed?
Can protein-rich foods trigger low blood sugar in HI/HA syndrome?
Does diazoxide work for children with HI/HA syndrome?
Can HI/HA syndrome affect a child's development?
Get notified when new evidence is published on Hyperinsulinism-hyperammonemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Hyperinsulinism-hyperammonemia Syndrome in an Infant with Seizures.
Strajnar A, Tansek MZ, Podkrajsek KT, et al.
Balkan journal of medical genetics : BJMG 2018; (21(1)):77-81 doi:10.2478/bjmg-2018-0014.
PMID: 30425915 - 2
Hyperinsulinism-hyperammonemia syndrome in two Peruvian children with refractory epilepsy.
De Los Santos-La Torre MA, Del Águila-Villar CM, Lu-de Lama LR, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(2)):207-211 doi:10.1515/jpem-2022-0490.
PMID: 36476334 - 3
Reverse Phenotyping: Addressing Refractory Seizures From an Endocrine Perspective.
Sherin S, Soodhana D, Mohanlal S, Pachat D
Cureus 2024; (16(12)):e75146 doi:10.7759/cureus.75146.
PMID: 39759686 - 4
Congenital Hyperinsulinaemic Hypoglycaemia-A Review and Case Presentation.
Krawczyk S, Urbanska K, Biel N, et al.
Journal of clinical medicine 2022; (11(20)) doi:10.3390/jcm11206020.
PMID: 36294341 - 5
Clinical and Molecular Spectrum of Glutamate Dehydrogenase Gene Defects in 26 Chinese Congenital Hyperinsulinemia Patients.
Su C, Liang XJ, Li WJ, et al.
Journal of diabetes research 2018; (2018()):2802540 doi:10.1155/2018/2802540.
PMID: 30306091 - 6
Hyperinsulinemic hypoglycemia: think of hyperinsulinism/hyperammonemia (HI/HA) syndrome caused by mutations in the GLUD1 gene.
Tran C, Konstantopoulou V, Mecjia M, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2015; (28(7-8)):873-6.
PMID: 25781533 - 7
Congenital Hyperinsulinemic Hypoglycemia and Hyperammonemia due to Pathogenic Variants in GLUD1.
Roy K, Satapathy AK, Houhton JAL, et al.
Indian journal of pediatrics 2019; (86(11)):1051-1053 doi:10.1007/s12098-019-02980-x.
PMID: 31119523 - 8
A severe case of hyperinsulinism due to hemizygous activating mutation of glutamate dehydrogenase.
Barrosse-Antle M, Su C, Chen P, et al.
Pediatric diabetes 2017; (18(8)):911-916 doi:10.1111/pedi.12507.
PMID: 28165182 - 9
Identification of the molecular dysfunction caused by glutamate dehydrogenase S445L mutation responsible for hyperinsulinism/hyperammonemia.
Grimaldi M, Karaca M, Latini L, et al.
Human molecular genetics 2017; (26(18)):3453-3465 doi:10.1093/hmg/ddx213.
PMID: 28911206 - 10
Glutamate dehydrogenase: role in regulating metabolism and insulin release in pancreatic β-cells.
Wilson DF, Cember ATJ, Matschinsky FM
Journal of applied physiology (Bethesda, Md. : 1985) 2018; (125(2)):419-428 doi:10.1152/japplphysiol.01077.2017.
PMID: 29648519 - 11
Robust regulation of hepatic pericentral amination by glutamate dehydrogenase kinetics.
Bera S, Lamba S, Rashid M, et al.
Integrative biology : quantitative biosciences from nano to macro 2016; (8(11)):1126-1132 doi:10.1039/c6ib00158k.
PMID: 27747338 - 12
Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children.
Ferrara C, Patel P, Becker S, et al.
The Journal of pediatrics 2016; (168()):212-219 doi:10.1016/j.jpeds.2015.09.045.
PMID: 26490124 - 13
Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1.
Aftab S, Gubaeva D, Houghton JAL, et al.
Endocrine connections 2023; (12(4)).
PMID: 35951311 - 14
Natural History of the Hyperinsulinism/Hyperammonemia Syndrome: A Retrospective Review Incorporating Patient-Centered Data.
Rosenfeld E, Taylor O, Mitteer LM, et al.
Hormone research in paediatrics 2026; 1-11 doi:10.1159/000551535.
PMID: 41980002 - 15
Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome.
Rosenfeld E, Nanga RPR, Lucas A, et al.
Orphanet journal of rare diseases 2022; (17(1)):248 doi:10.1186/s13023-022-02398-3.
PMID: 35752848 - 16
Hyperinsulinism hyperammonaemia (HI/HA) syndrome due to GLUD1 mutation: phenotypic variations ranging from late presentation to spontaneous resolution.
Brandt A, Agarwal N, Giri D, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(5)):675-679.
PMID: 32229669
This page explains HI/HA syndrome and its diagnostic process for educational purposes only; it does not replace medical advice. Your child's metabolic, neurology, and developmental care team should interpret test results and guide treatment.